U5P Stock Overview
A preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Vivani Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.12 |
| 52 Week High | US$5.30 |
| 52 Week Low | US$0.74 |
| Beta | 0 |
| 11 Month Change | -21.68% |
| 3 Month Change | -34.50% |
| 1 Year Change | 3.70% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -72.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| U5P | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 5.7% | 0.5% | -0.1% |
| 1Y | 3.7% | 0.9% | 2.4% |
Return vs Industry: U5P exceeded the German Medical Equipment industry which returned 0.9% over the past year.
Return vs Market: U5P exceeded the German Market which returned 2.4% over the past year.
Price Volatility
| U5P volatility | |
|---|---|
| U5P Average Weekly Movement | 12.4% |
| Medical Equipment Industry Average Movement | 4.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: U5P's share price has been volatile over the past 3 months.
Volatility Over Time: U5P's weekly volatility has decreased from 45% to 12% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 36 | Adam Mendelsohn | www.vivani.com |
Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes.
Vivani Medical, Inc. Fundamentals Summary
| U5P fundamental statistics | |
|---|---|
| Market cap | €64.13m |
| Earnings (TTM) | -€23.68m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.7x
P/E RatioIs U5P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| U5P income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$25.37m |
| Earnings | -US$25.37m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.46 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did U5P perform over the long term?
See historical performance and comparison